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Eperisone and afloqualone act by relaxing both skeletal and vascular smooth 
muscles to improve circulation and suppress pain reflex. These drugs are typi-
cally prescribed with non-steroidal anti-inflammatory drugs (NSAIDs) as 
painkillers. However, there have been no reports on serious adverse reactions 
to oral muscle relaxants; and this is the first report to describe three allergic re-
actions caused by eperisone and afloqualone. All three patients had histories of 
allergic reactions after oral intake of multiple painkillers, including oral mus-
cle relaxants and NSAIDs, for chronic muscle pain. An open-label oral chal-
lenge test was performed with each drug to confirm which drugs caused the 
systemic reactions. All patients experienced the same reactions within one 
hour after oral intake of eperisone or afloqualone. The severity of these reac-
tions ranged from laryngeal edema to hypotension. To confirm that the sys-
temic reaction was caused by eperisone or afloqualone, skin prick testing and 
intradermal skin tests were performed with eperisone or afloqualone extract in 
vivo, and basophil activity tests were performed after stimulation with these 
drugs in vitro. In one patient with laryngeal edema, the intradermal test with 
afloqualone extract had a positive result, and CD63 expression levels on baso-
phils increased in a dose-dependent manner by stimulation with afloqualone. 
We report three allergic reactions caused by oral muscle relaxants that might 
be mediated by non-immunoglobulin E-mediated responses. Since oral muscle 
relaxants such as eperisone and afloqualone are commonly prescribed for 
chronic muscle pain and can induce severe allergic reactions, we should pre-
scribe them carefully.
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INTRODUCTION
In Korea, eperisone and afloqualone together with non-steroidal anti-inflammatory 
drugs (NSAIDs) are commonly prescribed to control muscle pain. This is the first 
report of three anaphylactic reactions caused by eperisone and afloqualone.Gyu-Young Hur, et al.
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dyspnea and angioedema after taking painkillers, including 
eperisone and meloxicam, to treat back pain. She had been 
taking atenolol and enalapril for hypertension for over 15 
years, and had no history of any allergic reactions or other 
medical disease.
The patient’s chest X-ray, electrocardiogram (ECG), and 
routine laboratory findings were normal. She had no periph-
eral eosinophilia, although serum total IgE levels were ele-
vated to 401 IU/ML, and serum tryptase level was elevated 
to 32.5 μg/L. After recovery, open-label oral challenge tests 
were performed with eperisone and meloxicam separately. 
After taking 50 mg of eperisone, generalized urticaria and 
itching developed within one hour, and her blood pressure 
decreased from 150/100 mmHg to 120/80 mmHg.
SPT and an intradermal skin test with eperisone extract 
were performed, and results were all negative. An addition-
al oral challenge test with meloxicam gave a negative re-
sult. Therefore, she was confirmed as having an eperisone-
induced anaphylactic reaction.
Case 3
A 56-year-old woman experienced angioedema, hoarse-
ness, and dyspnea twice within 10 min after ingesting mul-
tiple painkillers, including afloqualone and talniflumate. 
She had no history of other allergic diseases and long-term 
medications. The ECG, radiological, and routine laboratory 
findings were normal. She had no peripheral eosinophilia, 
and serum total IgE levels were within normal limits. SPT 
to common inhalant allergens gave all negative responses. 
Open-label oral challenge tests were performed with aflo-
qualone and talniflumate separately. After taking 20 mg of 
afloqualone, a systemic reaction, including angioedema, 
nasal obstruction, hoarseness, and breathing difficulty, de-
veloped within 10 min. The patient’s vital signs were sta-
ble, but stridor was heard in the anterior chest. A neck X-ray 
showed laryngeal edema (Fig. 1). Her symptoms improved 
after treatment with corticosteroid and antihistamines. Al-
though SPT for afloqualone was negative, the intradermal 
test gave a positive response to 1 mg/mL afloqualone with a 
mean wheal size of 5 mm. The basophil activity test was 
performed to verify that the drug caused the systemic reac-
tion. The maximum CD63 levels from basophils obtained 
from the patient occurred upon incubation with 0.25 mg/
mL of afloqualone (46.1%) compared with the baseline val-
ue (25.5%) (Fig. 2). An oral challenge test with talniflumate 
gave a negative result.
The patient was confirmed as having an allergic reaction to 
CASE REPORT
Case 1
A 54-year-old woman with shoulder pain experienced two 
anaphylactic episodes after oral intake of several painkill-
ers, including eperisone and diclofenac. She had no history 
of other allergic diseases, but had taken an angiotensin re-
ceptor antagonist and metformin to control hypertension 
and diabetes for several years. Her anaphylactic reactions 
included generalized urticaria, angioedema, dyspnea, hypo-
tension, and dizziness. She visited the emergency room in 
both episodes and her symptoms were relieved after proper 
management.
She had no peripheral eosinophilia, although serum total 
immunoglobulin E (IgE) was elevated to 922 IU/mL. Skin 
prick testing (SPT) for common inhalant allergens showed all 
negative responses. Open-label oral challenge tests were per-
formed with eperisone and diclofenac separately to identify 
the causative drug. After taking 50 mg of eperisone, a system-
ic reaction developed within 30 min, which included general-
ized urticaria, cyanosis, and dizziness. The patient’s blood 
pressure dropped from 110/70 mmHg to 60/30 mmHg. She 
recovered fully after immediate administration of epinephrine, 
corticosteroid, and antihistamines. The results of SPT and an 
intradermal skin test with eperisone extract were negative. 
Since another challenge test with diclofenac also gave a nega-
tive result, she was confirmed as having an eperisone-induced 
anaphylactic reaction.
Case 2 
A 62-year-old woman visited the emergency room with 
Fig. 1. Neck X-rays taken after oral intake of afloqualone 20 mg, when stri-
dor and hoarseness were present, show supraglottic airway narrowing.Oral Muscle Relaxant Induced Allergic Reactions
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tions, all practitioners should bear in mind that oral muscle 
relaxants could cause drug-induced anaphylactic reactions.
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afloqualone, based on positive results in an open-label oral 
challenge test, intradermal test, and basophil activity test.
DISCUSSION
Eperisone and afloqualone are commonly prescribed oral 
muscle relaxants.1,2 They act centrally by relaxing skeletal 
and vascular smooth muscles to improve circulation and sup-
press pain reflex.3,4 These drugs are usually prescribed in 
combination with NSAIDs as painkillers. Although there have 
been a few reports of drug eruptions caused by eperisone, such 
as a fixed drug eruption,5 erythema, and angioedema,6 there 
has been no report of systemic adverse events, including 
anaphylactic reactions, to eperisone. There has been a single 
report of anaphylactic reactions caused by tolperisone, 
which is closely related to eperisone.7 In addition, there have 
been a few reports on afloqualone-induced drug eruptions 
limited to the skin.8 Therefore, this is the first report describ-
ing serious systemic adverse reactions, including anaphy-
laxis and laryngeal edema, caused by eperisone and aflo-
qualone. 
The first two cases were anaphylactic reactions that oc-
curred within 30 min after taking 50 mg of eperisone, and 
they were confirmed by oral provocation tests. In the sec-
ond case, this anaphylactic reaction could be augmented by 
daily intake of a beta-blocker and angiotensin-converting 
enzyme inhibitor, as verified by increased serum tryptase 
level. In the third case, laryngeal edema developed after 
taking afloqualone, which was confirmed by a neck radio-
graph, and the reaction was verified by positive responses to 
the intradermal test and basophil activity test, induced by 
afloqualone extract. Although there are no reports describ-
ing the underlying mechanisms of these allergic reactions, 
our findings suggest that the oral muscle relaxants de-
scribed herein could directly activate basophils to induce 
severe systemic reactions.
Oral muscle relaxants are commonly prescribed with 
NSAIDs to relieve pain. Therefore, practitioners might as-
sume that the causative drug is an NSAID, since aspirin and 
NSAIDs are the most common cause of anaphylaxis.9 How-
ever, since newly developed oral muscle relaxants, such as 
eperisone and afloqualone, can induce systemic allergic reac-
Fig. 2. Comparison of CD63 (%) levels following stimulation with calcium 
ionophore A2319 (3 μM; Sigma-Aldrich, St. Louis, MO, USA), anti-human 
goat IgE antibodies (1:100 vol/vol; KPL, Gaithersburg, MD, USA), and aflo-
qualone (0.005 and 0.25 mg/mL). IgE, immunoglobulin.
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